Cancer Biomarkers: Can We Turn Recent Failures into Success?
- 12 August 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 102 (19), 1462-1467
- https://doi.org/10.1093/jnci/djq306
Abstract
Disease biomarkers are used widely in medicine. But very few biomarkers are useful for cancer diagnosis and monitoring. Over the past 15 years, major investments have been made to discover and validate cancer biomarkers. Despite such investments, no new major cancer biomarkers have been approved for clinical use for at least 25 years. In the last decade, many reports have described new cancer biomarkers that promised to revolutionize the diagnosis of cancer and the management of cancer patients. However, many initially promising biomarkers have not been validated for clinical use. In this commentary, a plethora of parameters before sample analysis, during sample analysis, and after sample analysis that can complicate biomarker discovery and validation and lead to "false discovery" are discussed. Several examples of biomarker discoveries that were published in high-profile journals are also presented, as well as why they were not validated and the lessons learned from these false discoveries, so that similar mistakes can be avoided in the future.This publication has 37 references indexed in Scilit:
- Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery ToolMolecular & Cellular Proteomics, 2004
- Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential ProblemsJNCI Journal of the National Cancer Institute, 2004
- Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?Clinical Chemistry, 2003
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeClinical Chemistry, 2003
- Osteopontin as a potential diagnostic biomarker for ovarian cancer.JAMA, 2002
- Use of proteomic patterns in serum to identify ovarian cancerThe Lancet, 2002
- NMR — Another Cancer-Test DisappointmentThe New England Journal of Medicine, 1990
- Lack of Efficacy of Water-Suppressed Proton Nuclear Magnetic Resonance Spectroscopy of Plasma for the Detection of Malignant TumorsThe New England Journal of Medicine, 1990
- Proton Nuclear Magnetic Resonance Spectroscopy of Plasma from Healthy Subjects and Patients with CancerThe New England Journal of Medicine, 1990
- Detection of Malignant TumorsThe New England Journal of Medicine, 1986